Matches in Wikidata for { <http://www.wikidata.org/entity/Q92539207> ?p ?o ?g. }
Showing items 1 to 48 of
48
with 100 items per page.
- Q92539207 description "article scientifique publié en 2020" @default.
- Q92539207 description "artículu científicu espublizáu en marzu de 2020" @default.
- Q92539207 description "im März 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92539207 description "scientific article published on 01 March 2020" @default.
- Q92539207 description "наукова стаття, опублікована 1 березня 2020" @default.
- Q92539207 description "գիտական հոդված հրատարակված 2020 թվականի մարտի 1-ին" @default.
- Q92539207 name "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q92539207 type Item @default.
- Q92539207 label "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q92539207 prefLabel "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q92539207 P1433 Q92539207-8238966B-A020-4B33-A2FD-070EEDAEF735 @default.
- Q92539207 P1476 Q92539207-0223F110-6CD1-4DB4-8957-8111208131C0 @default.
- Q92539207 P2093 Q92539207-16C6D574-A1AF-4560-B4E6-5674F85C5777 @default.
- Q92539207 P2093 Q92539207-2E7FDB61-9EED-49F4-AF1C-E6D810A48BCE @default.
- Q92539207 P2093 Q92539207-49099145-7982-40EB-96CA-16D0D339CFC2 @default.
- Q92539207 P2093 Q92539207-59A50D90-E68C-43E8-82A5-233EC28F49EE @default.
- Q92539207 P2093 Q92539207-B5F279B7-13AD-4735-BDED-54BB6748FFF2 @default.
- Q92539207 P2093 Q92539207-D6646F9C-C26B-4C95-BB8F-9E9B202DA736 @default.
- Q92539207 P2093 Q92539207-F85A9A1C-0FDF-42AA-97BE-453C7229F9B8 @default.
- Q92539207 P2093 Q92539207-FF2BA3EF-5F0E-433B-89D0-5E57E70AEB95 @default.
- Q92539207 P304 Q92539207-0BC0BDE0-A79C-4B71-ADBE-38EF5BF13924 @default.
- Q92539207 P31 Q92539207-BE4B0FF2-03CA-4DC4-986C-0D06A39B024F @default.
- Q92539207 P356 Q92539207-30971751-E0BC-41D4-82A3-1C61DCEE469F @default.
- Q92539207 P433 Q92539207-56FA70CC-F52E-4250-A25C-CB99ED08CF7E @default.
- Q92539207 P478 Q92539207-4827EC7E-6E3E-45C6-9AC0-F58D926F4BD3 @default.
- Q92539207 P50 Q92539207-1496C0F0-70F3-4D26-9FCA-5542B4166119 @default.
- Q92539207 P577 Q92539207-233FA1CB-ECAA-4437-8B89-115159D5CA50 @default.
- Q92539207 P698 Q92539207-E2833AB8-F901-4DB5-AFCC-C58C0E2CCFD3 @default.
- Q92539207 P356 IZZ167 @default.
- Q92539207 P698 31400283 @default.
- Q92539207 P1433 Q15749161 @default.
- Q92539207 P1476 "Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center" @default.
- Q92539207 P2093 "Ann Gils" @default.
- Q92539207 P2093 "Annick Moens" @default.
- Q92539207 P2093 "Gert Van Assche" @default.
- Q92539207 P2093 "Griet Compernolle" @default.
- Q92539207 P2093 "Matthias Lenfant" @default.
- Q92539207 P2093 "Michiel Bronswijk" @default.
- Q92539207 P2093 "Sophie Tops" @default.
- Q92539207 P2093 "Séverine Vermeire" @default.
- Q92539207 P304 "628-634" @default.
- Q92539207 P31 Q13442814 @default.
- Q92539207 P356 "10.1093/IBD/IZZ167" @default.
- Q92539207 P433 "4" @default.
- Q92539207 P478 "26" @default.
- Q92539207 P50 Q110729292 @default.
- Q92539207 P577 "2020-03-01T00:00:00Z" @default.
- Q92539207 P698 "31400283" @default.